TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Bio Green Med Solution ( (BGMS) ) is now available.
On October 6, 2025, Bio Green Med Solution, Inc. finalized an Asset Purchase Agreement with Tethra Biosciences Inc. to sell certain assets, including all patent rights related to Plogosertib, a PLK 1 inhibitor, for $300,000 with a potential milestone payment of $170,000. This transaction marks a significant shift in Bio Green Med Solution’s operations, potentially impacting its market positioning and stakeholders by transferring key intellectual property to Tethra Biosciences.
Spark’s Take on BGMS Stock
According to Spark, TipRanks’ AI Analyst, BGMS is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on BGMS stock, click here.
More about Bio Green Med Solution
Bio Green Med Solution, Inc. operates in the biotechnology industry, focusing on developing treatments for advanced cancers and hematological malignancies.
Average Trading Volume: 1,694,990
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.23M
For an in-depth examination of BGMS stock, go to TipRanks’ Overview page.